We thank Michèl Willemsen and colleagues for their interest in the ATTeST trial of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia.1 The two doses studied in ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ... data from patients with Ataxia-Telangiectasia (A-T) treated ...

William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University ... of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem ...

including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications, related development and commercial-stage inflection point ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the online publication of safety data from ...

Ataxia-Telangiectasia (A-T), today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time. The webinar will feature leading A-T KOL Mary Kay Koenig, M.D., who will: 1) provide an A-T natural ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...